PCSK9 Inhibitor Eligibility (NICE TA393 / TA394)
Checks the NICE TA393 (alirocumab) / TA394 (evolocumab) LDL-C thresholds for adults with primary hypercholesterolaemia or mixed dyslipidaemia on maximal tolerated lipid-lowering therapy.
Score interpretation
PCSK9 monoclonal antibody not recommended by NICE for this population and LDL-C.
→ Optimise statin and ezetimibe; lifestyle measures; recheck lipids and reassess if LDL-C stays high.
LDL-C persistently above the NICE threshold despite maximal tolerated therapy.
→ Specialist (lipid clinic) initiation of evolocumab 140 mg every 2 weeks (TA394) or alirocumab (TA393); recheck LDL-C after treatment starts.
Interpretation bands for the PCSK9 Inhibitor. Apply clinical judgement and local guidance.
References
- NICE TA393. Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. 2016.
- NICE TA394. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. 2016.
Related
Curated clinical cross-links plus same-class fallbacks.
- Evolocumab · PCSK9 inhibitor monoclonal antibody
- Evolocumab · PCSK9 Inhibitor (Monoclonal Antibody)
- Alirocumab (PCSK9 Inhibitor — Post-ACS) · PCSK9 Inhibitor (Human Monoclonal Antibody)
- Alirocumab · Lipid-Lowering Agents
- Simvastatin with ezetimibe · HMG-CoA reductase inhibitor + cholesterol absorption inhibitor
- Bempedoic acid · ATP-citrate lyase inhibitor (lipid-lowering)
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.
